Unifarin2.5 mg

Unifarin 2.5 mg is an oral anticoagulant used for:

• Prevention and treatment of venous thrombosis (blood clots in the veins, such as deep vein thrombosis) and its extension, including pulmonary embolism
• Prevention of thromboembolic complications associated with atrial fibrillation and/or heart valve replacement
• Reducing the risk of death, recurrent heart attack, and thromboembolic events such as stroke after a myocardial infarction

Contains Unifarin 2.5 mg (as Unifarin 2.5 mg sodium) as the active ingredient, available as oral tablets in a wide range of strengths (commonly 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, and 10 mg), colour-coded by strength in many markets to help reduce dosing errors.

Unifarin 2.5 mg is a widely used oral anticoagulant ("blood thinner") that has been prescribed for decades to prevent and treat blood clots. It works by blocking the liver's ability to use vitamin K to produce several clotting factors, which reduces the blood's tendency to clot. Because the right dose varies enormously between individuals - influenced by genetics, diet, age, liver function, and interactions with many other medicines - Unifarin 2.5 mg requires regular blood testing (INR) to keep the anticoagulant effect within a safe and effective range, and it carries a boxed warning regarding the risk of serious or fatal bleeding.

Therapeutic Class: Anticoagulant

Unifarin 2.5 mg does not have an immediate anticoagulant effect, since it works by preventing the synthesis of new clotting factors rather than neutralizing those already circulating; a meaningful anticoagulant effect typically takes at least 5 days to develop, regardless of the INR result in the first few days, which is why an injectable anticoagulant (such as heparin) is generally used alongside Unifarin 2.5 mg for the first several days when treating an acute blood clot. Unifarin 2.5 mg is metabolized mainly by the liver enzyme CYP2C9, and individual variation in this enzyme, along with variation in the VKORC1 gene (involved in vitamin K recycling), explains much of the substantial dose variability seen between patients.

• Taken orally, once daily, at approximately the same time each day (often in the evening, to allow same-day INR results to guide that day's dose if needed)
• Can be taken with or without food
• Attend all scheduled INR blood tests, since your dose depends entirely on these results
• Eat a normal, balanced diet, maintaining a consistent amount of vitamin K intake from meal to meal, rather than making drastic changes (such as suddenly eating large amounts of green leafy vegetables)
• Do not start, stop, or change the dose of any other medicine, including over-the-counter products and herbal supplements, without checking whether it interacts with Unifarin 2.5 mg

Unifarin 2.5 mg has an extremely high number of clinically significant interactions, given its narrow therapeutic index; more frequent INR monitoring is needed whenever starting, stopping, or changing the dose of any interacting medicine:

• Antibiotics (many classes, including metronidazole, fluconazole, and several others): can significantly increase INR and bleeding risk; even short courses warrant closer INR monitoring.
• NSAIDs and aspirin: increase bleeding risk both through anticoagulant interaction and through their own effect on the stomach lining and platelets; generally avoided or used with extreme caution and close monitoring.
• Amiodarone: significantly increases Unifarin 2.5 mg's effect; a Unifarin 2.5 mg dose reduction is generally needed when starting amiodarone.
• Vitamin K-containing foods and supplements (particularly green leafy vegetables): can reduce Unifarin 2.5 mg's effect if intake increases suddenly; consistent, rather than avoided, intake is recommended.
• Herbal products (such as St. John's Wort, which reduces Unifarin 2.5 mg's effect, and ginkgo, ginseng, or garlic, which may increase bleeding risk): potential for interaction is significant and not always well studied; disclose all herbal and supplement use to your care team.
• Alcohol: acute heavy intake can increase Unifarin 2.5 mg's effect; chronic heavy use can decrease it (via liver enzyme induction).
• Many other prescription medicines across numerous classes can significantly raise or lower INR; always check with a pharmacist or doctor before starting or stopping any new medicine while on Unifarin 2.5 mg.

Common side effects

• Minor bruising
• Nosebleeds
• Bleeding gums

Serious side effects (boxed warning - seek urgent medical attention)

• Major or fatal bleeding: Unifarin 2.5 mg can cause bleeding that can be major or fatal; any organ system can be affected, and risk is related to the intensity of anticoagulation and patient-specific risk factors. Signs include unusual or severe bruising, blood in urine or stool (which may look dark or tarry), coughing up blood, severe headache, or unusual weakness - these require immediate medical attention.
• Skin necrosis (rare): a serious skin reaction, most often occurring within the first few days of treatment, sometimes associated with protein C deficiency; report any painful, discoloured skin lesion immediately.
• "Purple toe syndrome" (rare): a bluish-purple discoloration of the toes, usually occurring 3-8 weeks after starting treatment.

Pregnancy

Unifarin 2.5 mg is contraindicated in pregnancy in most circumstances, given a well-established risk of fetal harm ("Unifarin 2.5 mg embryopathy") and bleeding complications; it may be used in specific situations, such as certain mechanical heart valves, where a specialist team determines the benefit outweighs the fetal risk, under close, specialized monitoring.

Breastfeeding

Unifarin 2.5 mg is considered compatible with breastfeeding by multiple expert bodies, since it does not pass into breast milk in clinically significant amounts; nonetheless, nursing infants on Unifarin 2.5 mg-exposed milk should be monitored for unusual bruising or bleeding, particularly if the infant has additional risk factors.

• Bleeding risk (boxed warning): regular INR monitoring is essential to minimize this risk; instruct patients on signs of bleeding and the importance of prompt reporting.
• Delayed onset of action: Unifarin 2.5 mg cannot achieve a therapeutic effect within the first several days, regardless of INR trend; an injectable anticoagulant is generally used concurrently for acute clot treatment during this period.
• Numerous drug and food interactions: more frequent INR monitoring is needed whenever starting, stopping, or changing the dose of any other medicine, including short-term medicines like antibiotics.
• Genetic variability: individual sensitivity to Unifarin 2.5 mg varies substantially based on genetic factors; some patients require unusually low or high doses, which is why individualized titration and monitoring, rather than a fixed dose, is essential.
• Patient adherence and understanding of the need for consistent monitoring are essential for safe use; unsupervised use in patients unable to reliably attend monitoring appointments carries increased risk.

Overdose or excessive anticoagulant effect (reflected by a very high INR) increases the risk of serious or fatal bleeding, which may present as unusual bruising, blood in urine or stool, severe headache (possible intracranial bleeding), or signs of shock in severe cases. Management depends on the INR level and whether bleeding is present: for a very high INR without bleeding, oral vitamin K may be given; for bleeding or very high INR requiring urgent reversal, treatment may include IV vitamin K, prothrombin complex concentrate, or fresh frozen plasma, under close medical supervision. Suspected significant overdose or signs of bleeding require immediate medical attention.

Store at room temperature, protected from light and moisture, in the original container. Keep out of reach of children, given the serious risk of bleeding with accidental ingestion.

• Elderly: Often more sensitive to Unifarin 2.5 mg's anticoagulant effect and at higher bleeding risk; a lower starting dose and closer monitoring are generally used.
• Hepatic impairment: May potentiate Unifarin 2.5 mg's response, given decreased metabolism and impaired synthesis of clotting factors; use with caution and closer monitoring.
• Children: Used for specific pediatric indications with weight-based dosing and very close INR monitoring; infants fed a vitamin K-supplemented formula may show resistance to Unifarin 2.5 mg, while those with a human-milk diet may be more sensitive.
• CYP2C9/VKORC1 genetic variants: Genetic testing, where available, can help inform starting dose selection in some patients, alongside standard clinical factors.

Duration depends entirely on the indication - a defined period of several months for a first, provoked blood clot; longer-term or indefinite therapy for recurrent clots, certain mechanical heart valves, or ongoing atrial fibrillation with stroke risk factors - as determined by the treating physician based on the specific clinical situation and ongoing risk-benefit assessment.

Drug Class: Vitamin K antagonist (coumarin derivative)

Unifarin 2.5 mg blocks the vitamin K epoxide reductase enzyme in the liver, which is needed to recycle vitamin K into its active form. Without adequately recycled vitamin K, the liver cannot properly produce several essential clotting factors (factors II, VII, IX, and X) or two natural anticoagulant proteins (protein C and protein S), reducing the blood's overall ability to form clots. This is measured and monitored using the International Normalized Ratio (INR), a standardized blood test reflecting how long it takes blood to clot compared to normal.

Unifarin 2.5 mg is used in children for specific indications (such as certain congenital heart conditions or after valve surgery), with weight-based dosing and very close INR monitoring, since achieving consistent anticoagulation in children can be more difficult and requires frequent dose adjustment under specialist supervision.